Identification of New Candidate Vaccine Antigens Made by Streptococcus pyogenes: Purification and Characterization of 16 Putative Extracellular Lipoproteins

Journal of Infectious Diseases

Volumn 189, Issue 1, 2004, Pages 79-89

  Lei, Benfang ^a,b   Liu, Mengyao ^a   Chesney, Gillian L ^a,c   Musser, James M ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b MONTANA STATE UNIVERSITY   (United States)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LIPOPROTEIN; SPY0163 ANTIGEN; SPY0210 ANTIGEN; SPY0252 ANTIGEN; SPY0293 ANTIGEN; SPY0317 ANTIGEN; SPY0319 ANTIGEN; SPY0385 ANTIGEN; SPY0453 ANTIGEN; SPY0457 ANTIGEN; SPY0604 ANTIGEN; SPY0778 ANTIGEN; SPY0903 ANTIGEN; SPY1094 ANTIGEN; SPY1228 ANTIGEN; SPY1245 ANTIGEN; SPY1274 ANTIGEN; SPY1290 ANTIGEN; SPY1294 ANTIGEN; SPY1306 ANTIGEN; SPY1361 ANTIGEN; SPY1390 ANTIGEN; SPY1558 ANTIGEN; SPY1592 ANTIGEN; SPY1795 ANTIGEN; SPY1882 ANTIGEN; SPY2000 ANTIGEN; SPY2007 ANTIGEN; SPY2032 ANTIGEN; STREPTOCOCCUS ANTIGEN; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ANTIGEN PURIFICATION; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BIOINFORMATICS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG IDENTIFICATION; DRUG PURIFICATION; ESCHERICHIA COLI; EXPERIMENTAL INFECTION; FEMALE; GENE OVEREXPRESSION; GENE SEQUENCE; GENETIC CODE; GENOME ANALYSIS; GROWTH INHIBITION; HUMAN; MOLECULAR CLONING; MOUSE; NONHUMAN; OPEN READING FRAME; PHARYNGITIS; PRIORITY JOURNAL; PROTEIN PURIFICATION; SEROCONVERSION; SEROTYPE; STREPTOCOCCUS GROUP A; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PYOGENES; VACCINE PRODUCTION;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; CLONING, MOLECULAR; DISEASE MODELS, ANIMAL; ESCHERICHIA COLI; FASCIITIS, NECROTIZING; HUMANS; LIPOPROTEINS; MICE; MOLECULAR SEQUENCE DATA; OPEN READING FRAMES; PHARYNGITIS; RECOMBINANT PROTEINS; SEQUENCE HOMOLOGY, AMINO ACID; SPECIES SPECIFICITY; STREPTOCOCCAL INFECTIONS; STREPTOCOCCAL VACCINES; STREPTOCOCCUS PYOGENES; VACCINATION; VACCINES, SYNTHETIC;

EID: 1642498273     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/380491     Document Type: Article

References (61)

1. Cunningham MW. Pathogenesis of group A streptococcal infections. Clin Microbiol Rev 2000; 13:470-511.
2. Reid SD, Virtaneva K, Musser JM. Group A Streptococcus vaccine research: historical synopsis and new insights. In: Ellis RW, Brodeur BR, eds. New bacterial vaccines. Georgetown, TX: Landes Bioscience (in press).
3. Beachey EH, Seyer JM, Dale JB, Simpson WA, Kang AH. Type-specific protective immunity evoked by synthetic peptide of Streptococcus pyogenes M protein. Nature 1981; 292:457-9.
4. Brandt ER, Sriprakash KS, Hobb RI, et al. New multi-determinant strategy for a group A streptococcal vaccine designed for the Australian Aboriginal population. Nat Med 2000; 6:455-9.
5. Dale JB. Multivalent group A streptococcal vaccine designed to optimize the immunogenicity of six tandem M protein fragments. Vaccine 1999; 17:193-200.
6. Hu MC, Walls MA, Stroop SD, Reddish MA, Beall B, Dale JB. Immunogenicity of a 26-valent group A streptococcal vaccine. Infect Immun 2002; 70:2171-7.
7. Bessen D, Fischetti VA. Synthetic peptide vaccine against mucosal colonization by group A streptococci. I. Protection against a heterologous M serotype with shared C repeat region epitopes. J Immunol 1990; 145:1251-6.
8. Olive C, Clair T, Yarwood P, Good MF. Protection of mice from group A streptococcal infection by intranasal immunization with a peptide vaccine that contains a conserved M protein B cell epitope and lacks a T cell autoepitope. Vaccine 2002; 20:2816-25.
9. Olive C, Batzloff MR, Horvath A, et al. Potential of lipid core peptide technology as a novel self-adjuvanting vaccine delivery system for multiple different synthetic peptide immunogens. Infect Immun 2003; 71: 2373-83.
10. Batzloff MR, Hayman WA, Davies MR, et al. Protection against group A streptococcus by immunization with J8-diphtheria toxoid: contribution of J8-and diphtheria toxoid-specific antibodies to protection. J Infect Dis 2003; 187:1598-608.
11. Hirst GK, Lancefield RC. Antigenic properties of the type-specific substances derived from group A hemolytic streptococci. J Exp Med 1939; 69:425-45.
12. Schmidt WC. Type-specific antibody formation in man following injection of streptococcal M protein. J Infect Dis 1960; 106:250-5.
13. Cunningham MW, McCormack JM, Fenderson PG, Ho MK, Beachey EH, Dale JB. Human and murine antibodies cross-reactive with streptococcal M protein and myosin recognize the sequence GLN-LYS-SERLYS-GLN in M protein. J Immunol 1989; 143:2677-83.
14. Dale JB, Beachey EH. Multiple, heart-cross-reactive epitopes of streptococcal M proteins. J Exp Med 1985; 161:113-22.
15. de Malmanche SA, Martin DR. Protective immunity to the group A Streptococcus may be only strain specific. Med Microbiol Immunol (Berl) 1994; 183:299-306.
16. Villasenor-Sierra A, McShan WM, Salmi D, Kaplan EL, Johnson DR, Stevens DL. Variable susceptibility to opsonophagocytosis of group A streptococcus M-1 strains by human immune sera. J Infect Dis 1999; 180:1921-8.
17. Ji Y, Carlson B, Kondagunta A, Cleary PP. Intranasal immunization with C5a peptidase prevents nasopharyngeal colonization of mice by the group A Streptococcus. Infect Immun 1997; 65:2080-7.
18. Roggiani M, Stoehr JA, Olmsted SB, et al. Toxoids of streptococcal pyrogenic exotoxin A are protective in rabbit models of streptococcal toxic shock syndrome. Infect Immun 2000; 68:5011-7.
19. Kapur V, Maffei JT, Greer RS, Li LL, Adams GJ, Musser JM. Vaccination with streptococcal extracellular cysteine protease (interleukin-1β convertase) protects mice against challenge with heterologous group A streptococci. Microb Pathog 1994; 16:443-50.
20. McCormick JK, Tripp TJ, Olmsted SB, et al. Development of streptococcal pyrogenic exotoxin C vaccine toxoids that are protective in the rabbit model of toxic shock syndrome. J Immunol 2000; 165:2306-12.
21. Dale JB, Chiang EY, Liu S, Courtney HS, Hasty DL. New protective antigen of group A streptococci. J Clin Invest 1999; 103:1261-8.
22. Guzman CA, Talay SR, Molinari G, Medina E, Chhatwal GS. Protective immune response against Streptococcus pyogenes in mice after intranasal vaccination with the fibronectin-binding protein SfbI. J Infect Dis 1999; 179:901-6.
23. Kawabata S, Kunitomo E, Terao Y, et al. Systemic and mucosal immunizations with fibronectin-binding protein FBP54 induce protective immune responses against Streptococcus pyogenes challenge in mice. Infect Immun 2001; 69:924-30.
24. Stalhammar-Carlemalm M, Areschoug T, Larsson C Lindahl G. The R28 protein of Streptococcus pyogenesis related to several group B streptococcal surface proteins, confers protective immunity and promotes binding to human epithelial cells. Mol Microbiol 1999; 33:208-19.
25. Salvadori LG, Blake MS, McCarty M, Tai J, Zabriskie JB. Group A streptococcus-liposome ELISA antibody titers to group A polysaccharide and opsonophagocytic capabilities of the antibodies. J Infect Dis 1995; 171:593-600.
26. Lei B, Laura LM, Menning HM, et al. Identification and characterization of a novel heme-associated cell surface protein made by Streptococcus pyogenes. Infect Immun 2002; 70:4494-500.
27. Sutcliffe IC, Russell RRB. Lipoproteins of Gram-positive bacteria. J Bacteriol 1995; 177:1123-8.
28. Steere AC, Sikand VK, Meurice F, et al. Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. N Engl J Med 1998; 339:209-15.
29. Pizza M, Scarlato V, Masignani V et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 2000; 287:1816-20.
30. Brown JS, Ogunniyi AD, Woodrow MC, Holden DW, Paton JC. Immunization with components of two iron uptake ABC transporters protects mice against systemic Streptococcus pneumoniae infection. Infect Immun 2001; 69:6702-6.
31. Lissolo L, Maitre-Wilmotte G, Dumas P, Mignon M, Danve B, Quentin-Millet MJ. Evaluation of transferrin-binding protein 2 within the transferrin-binding protein complex as a potential antigen for future meningococcal vaccines. Infect Immun 1995; 63:884-90.
32. Myers LE, Yang YP, Du RP, et al. The transferrin binding protein B of Moraxella catarrhalis elicits bactericidal antibodies and is a potential vaccine antigen. Infect Immun 1998; 66:4183-92.
33. Potter AA, Schryvers AB, Ogunnariwo JA, Hutchins WA, Lo RYC, Watts T. Protective capacity of the Pasteurella haemolytica transferrin-binding proteins TbpA and TbpB in cattle. Microb Pathog 1999; 27: 197-206.
34. Rokbi B, Mignon M, Maitre-Wilmotte G, et al. Evaluation of recombinant transferrin-binding protein B variants from Neisseria meningitidis for their ability to induce cross-reactive and bactericidal antibodies against a genetically diverse collection of serogroup B strains. Infect Immun 1997; 65:55-63.
35. Talkington DF, Brown BG, Tharpe JA, Koenig A, Russell H. Protection of mice against fatal pneumococcal challenge by immunization with pneumococcal surface adhesin A (PsaA). Microb Pathog 1996; 21:17-22.
36. West D, Reddin K, Matheson M, et al. Recombinant Neisseria meningitidis transferrin binding protein A protects against experimental meningococcal infection. Infect Immun 2001; 69:1561-7.
37. Lei B, Mackie S, Lukomski S, Musser JM. Identification and immunogenicity of group A Streptococcus culture supernatant proteins. Infect Immun 2000; 68:6807-18.
38. Hoe NP, Nakashima K, Grigsby D, et al. Rapid molecular genetic subtyping of serotype M1 group A Streptococcus strains. Emerg Infect Dis 1999; 5:254-63.
39. Chen BPC, Hai T. Expression vectors for affinity purification and radiolabeling of proteins using Escherichia coli as host. Gene 1994; 139: 73-5.
40. Ferretti JJ, McShan WM, Ajdic D, et al. Complete genome sequence of an M1 strain of Streptococcus pyogenes. Proc Natl Acad Sci USA 2001; 98:4658-63.
41. Beres SB, Sylva GL, Barbian KD, et al. Genome sequence of a serotype M3 strain of group A Streptococcus: phage-encoded toxins, the high-virulence phenotype, and clone emergence. Proc Natl Acad Sci USA 2002; 99:10078-83.
42. Smoot JC, Barbian KD, Van Gompel JJ, et al. Genome sequence and comparative microarray analysis of serotype M18 group A Streptococcus strains associated with acute rheumatic fever outbreaks. Proc Natl Acad Sci USA 2002; 99:4668-73.
43. von Heijne G. The structure of signal peptides from bacterial lipoproteins. Protein Eng 1989; 2:531-4.
44. Sutcliffe IC, Harrington DJ. Pattern searches for the identification of putative lipoprotein genes in Gram-positive bacterial genomes. Microbiology 2002; 148:2065-77.
45. Reid SD, Green NM, Buss JK, Lei B, Musser JM. Multilocus analysis of extracellular putative virulence proteins made by group A Streptococcus: population genetics, human serologic response, and gene transcription. Proc Natl Acad Sci USA 2001; 98:7552-7.
46. Podbielski A, Pohl B, Woischnik M, et al. Molecular characterization of group A streptococcal (GAS) oligopeptide permease (Opp) and its effect on cysteine protease production. Mol Microbiol 1996; 21:1087-99.
47. Podbielski A, Leonard BA. The group A streptococcal dipeptide permease (Dpp) is involved in the uptake of essential amino acids and affects the expression of cysteine protease. Mol Microbiol 1998; 28:1323-34.
48. Janulczyk R, Pallon J, Björck L. Identification and characterization of a Streptococcus pyogenes ABC transporter with multiple specificity for metal cations. Mol Microbiol 1999; 34:596-606.
49. Haandrikman AJ, Kok J, Venema G. Lactococcal protease maturation protein PrtM is a lipoprotein. J Bacteriol 1991; 173:4517-25.
50. Smoot LM, Smoot JC, Graham MR, et al. Global differential gene expression in response to growth temperature alteration in group A Streptococcus. Proc Natl Acad Sci USA 2001; 98:10416-21.
51. Eichenbaum Z, Green BD, Scott JR. Iron starvation causes release from the group A Streptococcus of the ADP-ribosylating protein called plasmin receptor or surface glyceraldehyde-3-phosphate-dehydrogenase. Infect Immun 1996; 64:1956-60.
52. Griffiths BB, McClain O. The role of iron in the growth and hemolysin (streptolysin S) production in Streptococcus pyogenes. J Basic Microbiol 1988; 28:427-36.
53. McIver KS, Heath AS, Scott JR. Regulation of virulence by environmental signals in group A streptococci: influence of osmolarity, temperature, gas exchange, and iron limitation on emm transcription. Infect Immun 1995; 63:4540-2.
54. Kuboniwa M, Amano A, Shizukuishi S, Nakagawa I, Hamada S. Specific antibodies to Porphyromonas gingivalis Lys-Gingipain by DNA vaccination inhibit bacterial binding to hemoglobin and protect mice from infection. Infect Immun 2001; 69:2972-9.
55. Overweg K, Kerr A, Sluijter M, et al. The putative proteinase maturation protein A of Streptococcus pneumoniae is a conserved surface protein with potential to elicit protective immune responses. Infect Immun 2000; 68: 4180-8.
56. Lowther WT, Brot N, Weissbach H, Honek JF, Matthews BW. Thioldisulfide exchange is involved in the catalytic mechanism of peptide methionine sulfoxide reductase. Proc Natl Acad Sci USA 2000; 97:6463-8.
57. Etz H, Minh DB, Henics T, et al. Identification of in vivo expressed vaccine candidate antigens from Staphylococcus aureus. Proc Natl Acad Sci USA 2002; 99:6573-8.
58. McAtee CP, Fry KE, Berg DE. Identification of potential diagnostic and vaccine candidates of Helicobacter pylori by "proteome" technologies. Helicobacter 1998; 3:163-9.
59. Vytvytska O, Nagy E, Bluggel M, et al. Identification of vaccine candidate antigens of Staphylococcus aureus by serological proteome analysis. Proteomics 2002; 2:580-90.
60. Wizemann TM, Heinrichs JH, Adamou JE, et al. Use of a whole genome approach to identify vaccine molecules affording protection against Streptococcus pneumoniae infection. Infect Immun 2001; 69:1593-8.
61. Grifantini R, Bartolini E, Muzzi A, et al. Previously unrecognized vaccine candidates against group B meningococcus identified by DNA microarrays. Nat Biotechnol 2002; 20:914-21.